Pharmacology glossary
Receptor agonists, antagonists, and partial agonists: a functional glossary
Agonist and antagonist labels describe functional behavior in a defined receptor system. The observed response depends on receptor expression, signaling pathway, assay timing, and comparator, so the same ligand can appear different across experimental contexts.
Educational content only. Not medical advice.
Agonists produce a measurable receptor-mediated response
A full agonist can produce the system's defined maximal response under the assay conditions, while a partial agonist produces a lower maximum even when receptor occupancy is high. This comparison depends on the reference agonist and experimental system. Signal amplification and spare receptors can allow maximal functional response without occupying every receptor.
Antagonists reduce agonist responses through different mechanisms
A neutral antagonist has affinity but no activating efficacy in the measured pathway and blocks agonist action. Competitive antagonists often shift concentration-response relationships when competing at the same site, while noncompetitive or insurmountable behavior can reduce the observed maximum. Mechanistic classification requires experiments, not simply a lower signal.
Inverse agonists act on constitutive receptor activity
Some receptor systems signal in the absence of added agonist. An inverse agonist reduces that constitutive activity, whereas a neutral antagonist blocks other ligands without changing baseline signaling. Detecting the distinction requires an assay with measurable constitutive activity and suitable controls; otherwise the two can look identical.
Functional labels are pathway- and system-dependent
Receptor density, coupling proteins, cell background, readout, timing, desensitization, and pathway bias can change apparent efficacy and potency. A ligand described as partial in one assay may approach the system maximum in another with greater amplification. Responsible summaries name the receptor, pathway, model, and reference ligand rather than treat one label as universal.
Evidence limits
- Functional classification depends on the receptor system, pathway, timing, and reference agonist.
- Binding alone cannot determine whether a ligand is an agonist, antagonist, or inverse agonist.
- This glossary does not predict clinical outcomes from receptor labels.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
StatPearls, NCBI Bookshelf
Pharmacodynamics
Authoritative overview of receptors, agonism, antagonism, affinity, efficacy, potency, and response.
Open sourceAssay Guidance Manual, NCBI Bookshelf
Glossary of Quantitative Biology Terms
Institutional definitions for EC50, IC50, assay selectivity, accuracy, controls, and quantitative biology terms.
Open sourceAssay Guidance Manual, NCBI Bookshelf
Assay Operations for SAR Support
Authoritative guidance on concentration-response curves, curve fitting, variability, EC50, and IC50.
Open sourceCommon questions
Is a partial agonist just a weak agonist?
Not exactly. Partial refers to lower maximal efficacy in a defined system, not simply lower potency.
Can an antagonist bind tightly?
Yes. Affinity describes binding, while efficacy describes functional activation.
What is an inverse agonist?
It reduces constitutive receptor activity below baseline in a system where that activity is measurable.
Continue with context
Keep building your evidence-reading skills
Explore the public PeptideSchool research library for more source-backed methods, glossaries, and evidence maps.